132 related articles for article (PubMed ID: 34516133)
1. Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer.
Luo X; Cai G; Guo Y; Gao C; Huang W; Zhang Z; Lu H; Liu K; Chen J; Xiong X; Lei J; Zhou X; Wang J; Liu Y
J Med Chem; 2021 Sep; 64(18):13918-13932. PubMed ID: 34516133
[TBL] [Abstract][Full Text] [Related]
2. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment.
Li C; Yang X; Luo Y; Liu H; Zhong X; Zhou X; Zeng T; Tao L; Zhou Y; Gou K; Yang X; Liu X; Chen Q; Zhao Y; Luo Y
J Med Chem; 2021 Dec; 64(24):18175-18192. PubMed ID: 34905371
[TBL] [Abstract][Full Text] [Related]
4. Low cytotoxic quinoline-4-carboxylic acids derived from vanillin precursors as potential human dihydroorotate dehydrogenase inhibitors.
Petrović MM; Roschger C; Chaudary S; Zierer A; Mladenović M; Marković V; Trifunović S; Joksović MD
Bioorg Med Chem Lett; 2021 Aug; 46():128194. PubMed ID: 34116160
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold.
Li C; Zhou Y; Xu J; Zhou X; Liu S; Huang Z; Qiu Z; Zeng T; Gou K; Tao L; Zhong X; Yang X; Zhou Y; Su N; Chen Q; Zhao Y; Luo Y
Eur J Med Chem; 2022 Dec; 243():114737. PubMed ID: 36115209
[TBL] [Abstract][Full Text] [Related]
6. Bifunctional Naphtho[2,3-
Zuo Z; Liu X; Qian X; Zeng T; Sang N; Liu H; Zhou Y; Tao L; Zhou X; Su N; Yu Y; Chen Q; Luo Y; Zhao Y
J Med Chem; 2020 Jul; 63(14):7633-7652. PubMed ID: 32496056
[TBL] [Abstract][Full Text] [Related]
7. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
Zhang L; Zhang J; Wang J; Ren C; Tang P; Ouyang L; Wang Y
Eur J Med Chem; 2022 Mar; 232():114176. PubMed ID: 35151222
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.
Vyas VK; Variya B; Ghate MD
Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289
[TBL] [Abstract][Full Text] [Related]
10. A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer.
Lee J; Chen X; Wang Y; Nishimura T; Li M; Ishikawa S; Daikoku T; Kawai J; Tojo A; Gotoh N
Biochem Biophys Res Commun; 2021 Dec; 584():7-14. PubMed ID: 34753066
[TBL] [Abstract][Full Text] [Related]
11. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
13. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design.
Vyas VK; Qureshi G; Oza D; Patel H; Parmar K; Patel P; Ghate MD
Bioorg Med Chem Lett; 2019 Apr; 29(7):917-922. PubMed ID: 30738663
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a new structural class of competitive hDHODH inhibitors with in vitro and in vivo anti-inflammatory, immunosuppressive effects.
Shen W; Ren X; Zhu J; Xu Y; Lin J; Li Y; Zhao F; Zheng H; Li R; Cui X; Zhang X; Lu X; Zheng Z
Eur J Pharmacol; 2016 Nov; 791():205-212. PubMed ID: 27597161
[TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
Zhou WX; Chen C; Liu XQ; Li Y; Lin YL; Wu XT; Kong LY; Luo JG
Eur J Med Chem; 2021 Jan; 210():112980. PubMed ID: 33176943
[TBL] [Abstract][Full Text] [Related]
18. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
19. Potent human dihydroorotate dehydrogenase inhibitory activity of new quinoline-4-carboxylic acids derived from phenolic aldehydes: Synthesis, cytotoxicity, lipophilicity and molecular docking studies.
Petrović MM; Roschger C; Chaudary S; Zierer A; Mladenović M; Jakovljević K; Marković V; Botta B; Joksović MD
Bioorg Chem; 2020 Dec; 105():104373. PubMed ID: 33074120
[TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
